Microsoft announced AI for Health, a new $40 million program which is part of the AI for Good initiative that will leverage artificial intelligence technology to “empower researchers and organizations addressing some of the world’s toughest challenges in health.”
Novartis received approval from the U.S. Food and Drug Administration for the Swiss pharmaceuticals company’s drug Beovu to treat a cause of vision loss.
Paris-based GenSight Biologics reported the first group of data from Week 96 of the company’s RESCUE Phase III clinical trial.
The U.S. FDA approved Regeneron Pharmaceuticals Inc.’s Eylea (aflibercept) Injection for all stages of diabetic retinopathy, which is the leading cause of vision loss in diabetic patients.
A European Medicines Agency panel recommended approval of Spark Therapeutics’ gene therapy Luxturna for blindness, a move that also boosts Swiss drugmaker Novartis that bought the rights to one of the world’s costliest treatments outside the United States.
Swiss drugmaker Roche won a key European panel’s recommendation for its multiple sclerosis drug Ocrevus.
Hearing impairment is already linked to a heightened risk of cognitive decline in old age, and a new study suggests that impaired vision may carry the same risk.
Two Indian states have put sales of Swiss drugmaker Roche’s blockbuster drug Avastin on hold, officials said on Tuesday, after it hampered the vision of 15 patients who used it for a condition it is not officially meant to treat. Avastin is a cancer drug but is often used by doctors to treat vision […]